| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Medical Officer
2 companies
Leila Alland is Director at ABEO, with reported holdings spanning 2 companies. Leila Alland's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $754K at current prices.
Our model assigns Leila Alland a strong insider score of 81/100, based on 12 past trades. Over a 12-month horizon, 90.0% of those trades were profitable, with an average 12-month return of +43.6%.
Leila Alland's largest disclosed position is in ABEO as Director, worth about $691K. The ABEO filings lean toward selling, a net 25,311 shares.
Leila Alland has 22 Form 4 filings on record from April 2021 to June 2026, across 2 companies: Director at Abeona Therapeutics (ABEO), 2021–2026; Chief Medical Officer at PMV Pharmaceuticals (PMVP), 2021–2023.
The 37 reported transactions were 17 open-market sales, 8 stock awards, 7 option exercises and 4 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $52K and 11 sales worth about $1.0M.
The only open-market purchase was 11,000 shares of ABEO at an average $4.71 on May 16, 2024, about $52K. Twelve months later ABEO was up 33%.
The largest open-market sale was 4,471 shares of PMVP at an average $34.04 on August 9, 2021, about $152K. Twelve months later PMVP was down 56%.
None of the 4 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | ABEO Abeona Therapeutics Inc. | Director | Sell | 11,000 | $5.92 | $65,087.00 | -6.3% | -14.4% | - | |
| Feb 2, 2026 | ABEO Abeona Therapeutics Inc. | Director | Sell | 18,065 | $5.09 | $91,961.69 | -9.4% | +15.1% | - | |
| May 16, 2024 | ABEO Abeona Therapeutics Inc. | Director | Buy | 11,000 | $4.71 | $51,799.00 | +15.3% | +7.6% | +32.6% | |
| Sep 27, 2023 | ABEO Abeona Therapeutics Inc. | Director | Sell | 7,246 | $3.90 | $28,269.54 | -9.2% | +28.5% | +49.7% | |
| Sep 15, 2023 | PMVP Pmv Pharmaceuticals, Inc. | Chief Medical Officer | Sell | 6,291 | $6.62 | $41,646.42 | -12.1% | -66.0% | -77.5% | |
| Sep 9, 2021 | PMVP Pmv Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 100 | $30.25 | $3,025.00 | - | -13.7% | -52.8% | |
| Sep 7, 2021 | PMVP Pmv Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 3,900 | $30.25 | $117,975.00 | - | -20.2% | -51.4% | |
| Aug 9, 2021 | PMVP Pmv Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 4,471 | $34.04 | $152,202.15 | - | -30.0% | -55.6% | |
| Jul 7, 2021 | PMVP Pmv Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 4,000 | $32.30 | $129,213.11 | - | -7.2% | -49.8% | |
| Jun 7, 2021 | PMVP Pmv Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 4,000 | $33.60 | $134,386.84 | - | -13.7% | -67.5% |